Last updated: February 4, 2026
Case Overview
Sight Sciences, Inc. filed suit against Ivantis, Inc. in the U.S. District Court for the District of Delaware (Case No. 1:21-cv-01317). The core allegations involve patent infringement concerning minimally invasive glaucoma surgery (MIGS) devices. The case was initiated on March 30, 2021.
Allegations
Sight Sciences claims Ivantis infringed on patents related to its MIGS technology, specifically:
- Patent No. US9,901,282, issued February 20, 2018, titled "Device and Method for Glaucoma Treatment."
- Patent No. US9,873,862, issued January 23, 2018, titled "Implant and Delivery System."
Sight Sciences alleges Ivantis' Hydrus Microstent infringes multiple claims of these patents, focusing on device design and delivery mechanisms.
Procedural History
- Filing date: March 30, 2021
- Initial complaint filed in Delaware
- Counts include patent infringement, seeking injunctive relief and monetary damages
- Ivantis filed a motion to dismiss in late 2021, arguing patent invalidity and non-infringement
- Discovery proceedings commenced in 2022
- No settlement announced; case remains active as of early 2023
Legal Claims
Patent Infringement
Sight Sciences asserts that Ivantis' Hydrus Microstent and associated delivery tools infringe specific claims, including those related to the shape and placement of the implant and its delivery method. The patents emphasize a device designed for minimally invasive placement to reduce intraocular pressure.
Patent Validity and Non-Infringement Arguments
Ivantis challenges the validity of the patents, citing prior art and obviousness. It also claims non-infringement, asserting different device configurations and methods.
Key Legal Developments
- On December 10, 2021, Ivantis filed a motion to dismiss, which remains pending.
- Discovery disputes over claim construction and alleged infringing devices have been articulated.
- The case is progressing toward potential claim construction hearings.
Analysis
Patent Position and Market Impact
Sight Sciences holds patents that cover specific aspects of MIGS devices, aiming to protect its market share in glaucoma treatments. Ivantis' Hydrus is a direct competitor, with design features that potentially infringe on these patents.
The outcome could influence the competitive landscape for MIGS devices. An infringement finding would affirm Sight Sciences' patent rights, possibly leading to injunctions or licensing negotiations. A ruling of invalidity could open market access for Ivantis' devices and impact Sight Sciences' patent portfolio valuation.
Litigation Risks
- The validity of key patents is contested based on prior art references.
- The case timing aligns with increasing patent challenges within the ophthalmic surgical device space.
- The potential for settlement remains; however, court-ordered damages or injunctions could significantly impact market strategies.
Industry Context
This litigation occurs amid robust growth in the MIGS market, projected to reach $1.5 billion by 2025 (Fortune Business Insights). Patent disputes could slow product deployment and influence investment in R&D.
Financial and Strategic Implications
- The case underscores the importance of comprehensive patent portfolios in medtech.
- Court decisions may affect licensing negotiations, especially if patents are upheld.
- Market shares of Sight Sciences and Ivantis could shift based on litigation outcomes.
Conclusion
The litigation between Sight Sciences and Ivantis presents a high-stakes patent dispute over MIGS technology. Its resolution hinges on patent validity and infringement findings, with potential ripple effects across device development, commercialization, and market strategies in ophthalmic surgery.
Key Takeaways
- Sight Sciences alleges Ivantis infringed patents related to MIGS device design and delivery.
- Ivantis disputes infringement and validity, asserting prior art defenses.
- The case remains active, with procedural motions and discovery underway.
- Outcomes could influence patent protections and market dynamics for glaucoma treatment devices.
- Litigation highlights the importance of patent strategy in medtech innovation.
FAQs
1. What are the patents at stake in this litigation?
The patents involve device design and delivery methods for minimally invasive glaucoma surgery, specifically US9,901,282 and US9,873,862.
2. What is the current status of the case?
As of early 2023, the case is ongoing with a pending motion to dismiss and active discovery. No final judgment has been issued.
3. How might this case affect the MIGS market?
A ruling in favor of Sight Sciences could strengthen patent protections, limiting Ivantis' product offerings unless licensing is negotiated. An invalidity ruling could open the market further.
4. Are patent invalidity defenses common in medtech litigation?
Yes. Patent validity disputes based on prior art are standard, especially when litigants aim to challenge or defend patent rights.
5. Could the case lead to settlement?
Potentially. If damages or royalties are involved, parties may seek settlement to avoid lengthy litigation and market disruptions.
References
- U.S. Patent No. 9,901,282.
- U.S. Patent No. 9,873,862.
- Court Docket for Case No. 1:21-cv-01317, District of Delaware (Public records).
- Market data from Fortune Business Insights, "Global MIGS Devices Market," 2022.
